An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

Researchers excluded participants who had other chronic liver problems besides nonalcoholic fatty liver disease ... treatment modalities. The study in the NEJM showing possible benefits of ...

A new American Diabetes Association consensus statement provides guidance on screening, diagnosing, and managing metabolic ...

Fat cells are also metabolically active and can cause a chronic state of inflammation in the part of the body where they ...

A diabetes drug may soon double as a treatment for liver disease. Dapagliflozin, an SGLT-2 inhibitor typically used for type ...

Currently, the only approved treatment for MASH on the market is the thyroid hormone receptor β agonist resmetirom (Rezdiffra ...

The ability to not just halt but potentially reverse this scarring process could transform how we approach advanced liver disease treatment. Participants receiving semaglutide experienced an ...

Improves fibrosis and steatohepatitis Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a broad clinical spectrum, ranging from simple steatosis to metabolic ...

The Wall Street Journal reports on the expected FDA approval of lenacapavir and what it might mean for Gilead's future in the market. Other coverage of science and research-related news is on a ...

In this randomized controlled trial, oral semaglutide significantly reduced the risk of adverse cardiovascular events in ...